Litcius/Paper detail

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Amir Nutman, Jonathan Lellouche, Elizabeth Temkin, George L. Daikos, Anna Skiada, Emanuele Durante‐Mangoni, Yael Dishon‐Benattar, Roni Bitterman, Dafna Yahav, Vered Daitch, Mariano Bernardo, Domenico Iossa, Oren Zusman, Lena E. Friberg, Johan W. Mouton, Ursula Theuretzbacher, Leonard Leibovici, Mical Paul, Yehuda Carmeli, Mical Paul, Yael Dishon Benattar, Yaakov Dickstein, Roni Bitterman, Hiba Zayyad, Fidi Koppel, Yael Zak-Doron, Sergey Altunin, Nizar Andria, Ami Neuberger, Anat Stern, Neta Petersiel, Marina Raines, Amir Karban, Leonard Leibovici, Dafna Yahav, Noa Eliakim‐Raz, Oren Zusman, Michal Elbaz, Heyam Atamna, Vered Daitch, Tanya Babich, Yehuda Carmeli, Amir Nutman, Amos Adler, Inbar Levi, George L. Daikos, Anna Skiada, Ioannis Pavleas, Anastasia Antoniadou, Antigoni Kotsaki, Emanuele Durante‐Mangoni, Roberto Andini, Domenico Iossa, Mariano Bernardo, Giusi Cavezza, Lorenzo Bertolino, Giuseppe Giuffrè, Roberto Giurazza, Susanna Cuccurullo, Maria Galdo, Patrizia Murino, Adriano Cristinziano, Antonio Corcione, Rosa Zampino, Pia Clara Pafundi, Johan W. Mouton, Lena E. Friberg, Anders Kristoffersson, Ursula Theuretzbacher

2020Clinical Microbiology and Infection78 citationsDOI

Topics & Concepts

MeropenemColistinCarbapenemGram-negative bacterial infectionsMedicineGramMicrobiologyCarbapenem-resistant enterobacteriaceaeAntibioticsEnterobacteriaceaeBiologyBacteriaAntibiotic resistanceEscherichia coliGeneticsGeneBiochemistryAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes | Litcius